1. What Is the Psilocybin Market?
The Psilocybin Market covers synthetic and natural psilocybin drug products, psilocybin-assisted therapy clinical programs, licensed service center operations, and research drug supply for therapeutic use in treatment-resistant depression, anxiety, PTSD, and addiction management. Psychiatric research institutions, clinical-stage drug developers, licensed psilocybin service centers, and therapy training organizations participate in a regulated therapeutic ecosystem advancing psilocybin from Schedule I classification toward mainstream clinical medicine. The market reflects growing investment in pharmaceutical-grade psilocybin synthesis, clinical trial infrastructure, facilitated therapy model development, and regulatory engagement programs advancing psilocybin therapeutic legitimacy.
2. Psilocybin Market Size & Forecast
3. Emerging Technologies
- Pharmaceutical-grade synthetic psilocybin synthesis facilities meeting GMP standards are advancing as supply infrastructure for clinical trials and eventual commercial drug production at scales required for widespread prescription access. Growing adoption of pharmaceutical psilocybin manufacturing is driven by clinical trial demand for reliable GMP-compliant supply and the commercial preparation requirements of companies approaching regulatory submission.
- Psilocybin-assisted therapy outcome measurement frameworks validated against standard psychiatric outcome scales are advancing as clinical evidence tools enabling cross-trial data comparison and regulatory submission support. Increasing adoption of measurement frameworks by clinical research organizations is driven by regulatory requirements for validated outcome measures and the comparative effectiveness evidence base that reimbursement decisions require.
- Psilocybin retreat and wellness program operators working within legal frameworks in the Netherlands, Jamaica, and Costa Rica are advancing as commercial access models serving global wellness tourism demand. Growing adoption among wellness retreat operators is driven by international consumer demand from populations in jurisdictions where psilocybin access remains restricted, creating medical tourism revenue opportunities.
- Digital therapeutic integration platforms providing AI-supported preparation, session documentation, and post-session integration support are advancing as adjunct tools for facilitated psilocybin therapy programs. Increasing deployment at psilocybin therapy clinics and service centers is driven by evidence that structured digital integration support improves durable therapeutic outcomes beyond the acute psilocybin session.
Similar technologies are also transforming adjacent markets. Learn more in our Medical Cannabis Market.
4. Key Market Opportunity
Revenue is concentrated in the Psilocybin Market at the clinical trial drug supply and licensed service center sub-market, where pharmaceutical-grade psilocybin commands premium pricing for regulated clinical and commercial therapeutic access. The pharmaceutical psilocybin drug approval opportunity is the highest long-term value driver, as Compass Pathways' COMP360 and competing Phase 3 programs advance toward the first prescription psilocybin drug approval creating healthcare reimbursement market access. Oregon and Colorado regulated psilocybin service operations represent a growing commercial revenue area as licensed service center capacity expands and consumer awareness drives session demand beyond initial early-adopter populations. Novel psilocybin analog drug development represents an emerging opportunity as second-generation compounds entering clinical trials target more accessible therapy formats for standard psychiatric clinic delivery.
5. Top Companies in the Psilocybin Market
The following organisations hold leading positions in the Psilocybin Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Compass Pathways plc
- Usona Institute
- Beckley Psytech
- GH Research
- ATAI Life Sciences (Perception Neuroscience)
- Numinus Wellness
- Synthesis Institute
- TheraPsil
- Oregon-Licensed Service Centers
- Fluence Training
- Erowid Center
- Cybin Inc.
6. Market Segmentation
The Psilocybin Market is analysed across 7 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product Type | Synthetic Psilocybin Natural Extract Psilocybin Formulated Drug Product Novel Psilocybin Analogs |
| By Therapy Model | Psilocybin-Assisted Psychotherapy Psilocybin Service Center Facilitated Experience Retreats and Wellness Programs |
| By Indication | Treatment-Resistant Depression Major Depressive Disorder End-of-Life Anxiety Addiction and Substance Use PTSD |
| By Distribution | Hospital Formulary Licensed Service Centers Research Supply Regulated Retail |
| By Phase | Commercial Market Clinical Trial Stage Preclinical Research |
| By Company Type | Pharmaceutical Drug Developers Psilocybin Service Operators Research Supply Companies |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Psilocybin Market trajectory over the forecast period:
Compass Pathways' Phase 3 Trials Are the Most Advanced Pharmaceutical Psilocybin Program Globally.COMP360 psilocybin therapy for treatment-resistant depression is generating clinical efficacy data across multi-center Phase 3 trials, advancing toward the first global regulatory submission for a pharmaceutical psilocybin drug. Compass Pathways reported positive COMP360 Phase 3 interim data in 2024, with the trial generating remission outcomes at rates exceeding comparator treatment-resistant depression study benchmarks.
Oregon's Psilocybin Service Centers Are Generating the First Commercial Psilocybin Market Data.Licensed Oregon service centers conducting facilitated psilocybin sessions under Measure 109 are generating real-world safety and outcome data that supports regulatory confidence in commercial psilocybin access models. Multiple Oregon psilocybin service centers expanded operations and published voluntary outcome reporting in 2024, demonstrating session safety profiles and participant-reported improvement in depression and anxiety metrics.
Novel Psilocybin Analogs Targeting Faster-Acting or Lower-Duration Therapeutic Effects Are Advancing.Second-generation psilocybin analog compounds including tabernanthalog and short-acting derivatives are entering Phase 1 trials, designed to separate the antidepressant mechanism from the prolonged hallucinogenic session format. GH Research and Beckley Psytech advanced proprietary psilocybin analog clinical programs in 2024, targeting faster-onset or shorter-duration profiles designed for compatibility with outpatient psychiatric treatment settings.
For related market intelligence, see the Psychedelic Market.
8. Segmental Analysis
By product type, the Synthetic Psilocybin segment dominated the Psilocybin Market in 2025, representing the largest revenue share as pharmaceutical-grade synthetic psilocybin supplied regulated clinical trials and Oregon service center operations. The Novel Psilocybin Analogs segment is the fastest-growing product type category, advancing as second-generation compounds targeting shorter duration or non-hallucinogenic mechanisms enter human clinical trials.
By indication, the Treatment-Resistant Depression segment dominated the Psilocybin Market in 2025, reflecting the concentration of Phase 3 clinical trial investment and regulatory development activity in this high-unmet-need indication. The Major Depressive Disorder segment is the fastest-growing indication category, driven by clinical trial expansion into broader depression populations where psilocybin's rapid-acting antidepressant effect shows clinical relevance.
9. Regional Analysis
Regional demand patterns across the Psilocybin Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Psilocybin Market in 2025, holding 48.0% of the global market. 0%. Oregon and Colorado's regulated psilocybin service frameworks represent the world's first legal commercial psilocybin markets, while US-based Compass Pathways and ATAI Life Sciences anchor the global pharmaceutical development ecosystem. NIH funding for psilocybin research at Johns Hopkins University, NYU, and UCLA creates academic clinical trial infrastructure that generates peer-reviewed evidence advancing regulatory and physician acceptance. Strong venture capital investment in US psilocybin drug development companies and the growing number of US-based clinical trial sites create a commercially active development and emerging services ecosystem.
Highest CAGR Region
Europe is expected to register the highest CAGR of 19.5% during the forecast period. Swiss compassionate use psilocybin programs, Netherlands psychedelic retreat infrastructure, and UK MHRA engagement with psilocybin clinical development programs create early legal market access across progressive European jurisdictions. Australian TGA authorization for psilocybin in treatment-resistant depression provides a regulatory precedent that European regulators and companies are monitoring as a pathway model for EU regulatory engagement. Growing European clinical trial investment by Compass Pathways, GH Research, and Beckley Psytech is building multi-site trial infrastructure that creates regional regulatory familiarity and accelerates potential approval timelines.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Psilocybin Market was valued at USD 1.12 Bn in 2025 and is projected to reach USD 3.96 Bn by 2034, growing at a CAGR of 15.00% over the 2026–2034 forecast period.
The Psilocybin Market is projected to grow at a CAGR of 15.00% from 2026 to 2034.
North America accounted for the largest share of the Psilocybin Market in 2025, holding 48.0% of the global market.
The leading companies in the Psilocybin Market include Compass Pathways plc, Usona Institute, Beckley Psytech, GH Research, ATAI Life Sciences (Perception Neuroscience), Numinus Wellness, Synthesis Institute, TheraPsil, Oregon-Licensed Service Centers, Fluence Training, Erowid Center, Cybin Inc..
Compass pathways' phase 3 trials are the most advanced pharmaceutical psilocybin program globally.
By product type, the Synthetic Psilocybin segment dominated the Psilocybin Market in 2025, representing the largest revenue share as pharmaceutical-grade synthetic psilocybin supplied regulated clinical trials and Oregon service center operations.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 6 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 6 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 6 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.